Literature DB >> 22851836

Controversies and challenging therapeutic modalities in gastric cancer.

Sotiria Mastoraki, Aikaterini Mastoraki, Nikolaos Lefantzis, Panagiotis Safioleas, George Sakorafas, Michael Safioleas.   

Abstract

Gastric cancer is still the fourth common neoplasm worldwide. Gastric ulcers, adenomatous polyps, and intestinal metaplasia have been associated with an increased relative risk. Tissue diagnosis and anatomic localization of the primary tumor are best obtained by upper gastrointestinal endoscopy. Despite new screening techniques peritoneal tumor spread and occult liver and lymph node metastases are only detected intra-operatively. Therapy is becoming more and more complex comprising surgical resection, investigational neoadjuvant, adjuvant or palliative chemotherapy, or supportive care. Complete surgical eradication of a tumor with resection of adjacent lymph nodes represents the best chance for long-term survival. The choice of operation depends upon the location of the tumor, the clinical stage, and the histologic type. Chemotherapy can provide symptom palliation, improve quality of life, and prolong survival in patients with advanced gastric cancer. Preoperative radiation therapy may allow for tumor downstaging and reduced probability of residual microscopic disease at surgery.

Entities:  

Keywords:  Gastric cancer; Literature review; Therapeutic approach

Year:  2011        PMID: 22851836      PMCID: PMC3144344          DOI: 10.1007/s12262-011-0285-7

Source DB:  PubMed          Journal:  Indian J Surg        ISSN: 0973-9793            Impact factor:   0.656


  40 in total

1.  Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via suppression of tumor angiogenesis.

Authors:  Jo Tokuyama; Tetsuro Kubota; Yoshiro Saikawa; Masashi Yoshida; Toshiharu Furukawa; Yoshihide Otani; Koichiro Kumai; Masaki Kitajima
Journal:  Anticancer Res       Date:  2005 Jan-Feb       Impact factor: 2.480

2.  Laparoscopic completion total gastrectomy in remnant gastric cancer: technical detail and experience of two cases.

Authors:  Jyewon Song; Jeong Yoen Kim; Sungsoo Kim; Won Hyuk Choi; Jae Ho Cheong; Woo Jin Hyung; Seung Ho Choi; Sung Hoon Noh
Journal:  Hepatogastroenterology       Date:  2009 Jul-Aug

3.  Laparoscopic minilaparotomy Billroth I gastrectomy with extraperigastric lymphadenectomy for early gastric cancer using an abdominal wall-lifting method.

Authors:  I Uyama; H Ogiwara; T Takahara; T Furuta; K Kikuchi; S Iida
Journal:  J Laparoendosc Surg       Date:  1995-06

4.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.

Authors:  J S Macdonald; S R Smalley; J Benedetti; S A Hundahl; N C Estes; G N Stemmermann; D G Haller; J A Ajani; L L Gunderson; J M Jessup; J A Martenson
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

5.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

6.  Early gastric cancer: prognostic factors in 223 patients.

Authors:  S Folli; M Dente; D Dell'Amore; M Gaudio; O Nanni; L Saragoni; A Vio
Journal:  Br J Surg       Date:  1995-07       Impact factor: 6.939

7.  Expression of membrane-type matrix metalloproteinase in human gastric carcinomas.

Authors:  H Nomura; H Sato; M Seiki; M Mai; Y Okada
Journal:  Cancer Res       Date:  1995-08-01       Impact factor: 12.701

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

10.  Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.

Authors:  Jaffer A Ajani; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Lucile Awad; Eric Van Cutsem
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.